The Ritedose Corporation

The Ritedose Corporation is the largest contract development and manufacturing organization (CDMO) in the United States specializing in sterile Blow-Fill-Seal (BFS) technology. Founded in 1995 and headquartered in Columbia, South Carolina, Ritedose operates as both an industry-leading CDMO and a powerhouse generic pharmaceuticals manufacturer. The company has delivered over 12 billion doses of critical medications since 2012 with no patient interruptions. Ritedose's core competency is the BFS automated process, which blows extruded polymer into a mold, fills the formed container with product, and seals it in a continuous aseptic operation—increasing efficiency, quality, and safety. The company operates 100,000+ square feet of manufacturing facilities with approximately 200 employees and manufactures 1.8 billion doses annually. Ritedose's generic pharmaceutical division distributes products to wholesalers, major retail pharmacy chains, and hospitals across the US, with a focus on respiratory inhalation solutions (nebulized products). The company holds FDA approvals for multiple generic inhalation products including Albuterol Sulfate, Formoterol Fumarate, Arformoterol Tartrate, Cromolyn Sodium (oral and inhalation), and Tobramycin Inhalation Solution. Recent expansions include a $17 million investment in cGMP laboratory infrastructure and a state-of-the-art distribution and logistics facility at Ritedose Performance Park. Ritedose also manufactures specialty formulations including prefilled syringes for vaccines and single-dose syringe products for critical care applications. The company is ISO 13485 certified and operates under FDA cGMP compliance. Ritedose serves major pharmaceutical partners including Viatris, Verona Pharma, Cipla, Novartis, Lupin, Amneal, and others.